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One of the most common situations in which we see gene
conversion is in cancer, for which loss of heterozygosity is
an important consideration. The mechanisms regulating
gene conversion and the selection of proper donor
sequences are not well understood, so Cummings et al.
attack this using a cell culture system and ﬁnd a role for
epigenetic modiﬁcation in the regulation of gene conver-
sion. DT40 cells are a chicken B cell line that continues
to diversify immunoglobulin (Ig) chains through gene
conversion. Through use of a lac system, the authors tether
modiﬁers of chromatin activation—either VP16 or HIRA—
to donor sequences and ﬁnd that either protein increases
the rate of gene conversion by 10-fold. This stimulation
works through epigenetic mechanisms, although the two
proteins use distinct epigenetic marks. Whereas VP16
increases the level of acetylated histones H3 and H4 in
the donor sequences, HIRA alters the distribution of nucle-
osomes and increases histone H3.3. Thus, although epige-
netic modiﬁcations inﬂuence gene conversion, it appears
that this can occur through multiple, distinct marks.
Cummings et al. (2008). PLOS One 3, e4075. 10.1371/
journal.pone.0004075.
DNA Demethylation Resembles DNA Repair
An important way in which cells modulate gene expres-
sion is through cytosinemethylation at CpG dinucleotides
in gene promoters. Multiple DNA methyltransferases have
been characterized, but the process of demethylation is
more of a mystery. Two recent papers suggest that deme-
thylation occurs in a DNA repair-like fashion, rather than
through the simple removal of a methyl group. Both
papers implicate Gadd45 proteins as having a role in active
DNA demethylation. First, in zebraﬁsh embryos, Rai et al.
ﬁnd active demethylation of a microinjected in vitro-
methylated DNA fragment. The process they observe
appears to occur in two steps: methylcytosine deamination
mediated by AID, followed by thymine base excision from
a G:T intermediate, performed by the thymine glycosylase
Mbd4. This process is promoted by Gadd45 family
members, albeit through a mechanism that is unclear. In
addition to being involved in demethylation in an artiﬁcial
system, Ma et al. observed a role for a Gadd45 protein
in vivo. In mice, synchronous neuronal activation by elec-troconvulsive treatment induced DNA demethylation and
subsequent increases in expression of genes involved in
adult neurogenesis, including BDNF and FGF. This process
required Gadd45b, and it is a novel mechanistic link
between transient neural activation and adult neurogene-
sis. Both papers put Gadd45 proteins at the scene of active
DNA demethylation, but more work is required to fully
unravel their role in this process.
Ma et al. (2009). Science, in press. Published online January
1, 2009. 10.1126/science.1166859.
Rai et al. (2008). Cell 135, 1201–1212.
Melatonin Receptor Associated with Plasma
Glucose Levels
Four papers in the January issue ofNature Genetics link a key
player in regulation of circadian rhythms with fasting
plasma glucose levels and with risk of type 2 diabetes
(T2D). SNPs in MTNR1B, which encodes the melatonin
receptor 2, were associated with fasting plasma glucose
even in samples of healthy, nondiabetic individuals, and
they also predicted risk of T2D in multiple prospective
samples. Melatonin is believed to inhibit insulin secretion,
and there is an inverse relationship between the levels of
melatonin and insulin over the course of the circadian
cycle. In support of this relationship, Lyssenko et al. and
Bouatia-Naji et al. both show that MTNR1B is expressed in
pancreatic islets. Further, Lyssenko et al. demonstrate that
beta cells incubated with melatonin secrete less insulin.
Together, thesepapers provide strong support thatMTNR1B
is involved in glucosehomeostasis, and they suggest anovel
therapeutic avenue for the prevention or treatment of T2D.
Sabatti et al. (2009). Nat. Genet. 41, 35–46.
Prokopenko et al. (2009). Nat. Genet. 41, 77–81.
Lyssenko et al. (2009). Nat. Genet. 41, 82–88.
Bouatia-Naji et al. (2009). Nat. Genet. 41, 89–94.
Expanding the 15q13.3 Microdeletion Phenotype
Over the last year, microdeletions at chromosome 15q13.3
have been reported in people with schizophrenia, autism
spectrum disorder, and a syndrome of mental retardation,
epilepsy, and dysmorphic features. Helbig et al. report that
the same microdeletions at 15q13.3 are even more
commonly associated with idiopathic generalized epilepsy.
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disability or dysmorphic features, so they do not appear to
have the previously described mental retardation and
epilepsy syndrome. Penetrance appears to be an important
consideration for these microdeletions; analysis of ﬁve sets
of parental samples revealed three apparently unaffected
carriers of the same deletion. A fourth parent also carried
the deletion but had panic disorder, a phenotype that
has already been associated with this microdeletion. This
is the most common genetic risk factor identiﬁed for the
generalized epilepsies to date. The obvious candidate
gene in the deleted region is CHRNA7, which encodes
a subunit of the nicotinergic acetylcholine receptor.
Helbig et al. (2009). Nat. Genet. Published online January
11, 2009. 10.1038/ng.292.
Treatment of Hemophilia A in Mice with Induced
Pluripotent Cells
Through demonstrated survival of a normally fatal
bleeding assay by mice with hemophilia A, Xu et al. have100 The American Journal of Human Genetics 84, 99–100, Februarybeen the second group successful in their attempt to use
induced pluripotent (iPS) cells to correct a monogenic
disorder in mice. The wild-type iPS cells used in their study
were derived from tail tip ﬁbroblasts of a C57BL/6 mouse,
a close relative of the hemophilia A mouse model. They
were used to generate endothelial cells that were directly
injected into the livers of affected mice. This treatment
resulted in increased factor VIII expression in multiple
organs with plasma factor VIII levels up to 12% of that in
controls. This work follows on the heels of Hanna et al.
(Science 318, 1920–1923), who successfully treated sickle
cell disease in a mouse using autologous iPS cells derived
from tail tip ﬁbroblasts. The genetic defect in the iPS cells
was corrected in a targeted fashion, and they were used
to make bone marrow cells for transplant. Concerns still
exist regarding the use of viral vectors to express the factors
needed to generate iPS cells, but these studies show that
working out these issues could lead to valuable treatments
for some Mendelian disorders.
Xu et al. (2009). Proc. Natl. Acad. Sci. U. S. A. 106,
808–813.13, 2009
